CD19 and acute lymphoblastic leukemia: While anti-CD19 CAR-T therapy has significantly prolonged the median survival of r/r B-ALL patients [35], many of these patients subsequently face disease progression, predominantly due to therapeutic resistance stemming from antigen loss [14].